Medtronic (MDT) risk factors: FY2026 10-K

1. We operate in a highly competitive industry and we may be unable to compete effectively.
2. Our success depends on our ability to differentiate our products and successfully execute and scale emerging technologies.new
3. Reduction or interruption in supply or other manufacturing difficulties may adversely affect our manufacturing operations and related product sales.
4. Our research and development efforts rely upon investments and investment collaborations, and we cannot guarantee that any previous or future investments or investment collaborations will be successful.
5. Failure to identify, execute, and integrate acquired businesses into our operations successfully, or challenges related to the Company's strategic initiatives, including divestitures and third-party funding arrangements, as well as liabilities or claims relating to such acquired businesses, divestitures, or arrangements could adversely affect our business.reworded
6. We have debt obligations that create risk.
7. Public health crises have had, and may continue to have, an adverse effect on certain aspects of our business, results of operations, financial condition, and cash flows. The nature and extent of future impacts are highly uncertain and unpredictable.

Read these in Item 1A · See the changes

1. We are subject to extensive and complex laws and governmental regulations and any adverse regulatory action may materially adversely affect our financial condition and business operations.
2. Quality problems have in the past and could in the future lead to recalls or safety alerts, product liability claims, reputational harm, adverse verdicts or costly settlements, and could have a material adverse effect on our business, results of operations, financial condition, and cash flows.
3. Our failure to comply with laws and regulations relating to reimbursement of healthcare goods and services, or changes to such laws, coverage policies, and payment practices, may subject us to penalties and adversely impact demand, our reputation, business, results of operations, financial condition, and cash flows.reworded
4. We are substantially dependent on patent and other proprietary rights and failing to protect such rights or to be successful in litigation related to our rights or the rights of others may result in our payment of significant monetary damages and/or royalty payments, negatively impacting our ability to sell current or future products.
5. Healthcare policy changes may have a material adverse effect on us.
6. We are subject to litigation, claims, investigations, and regulatory proceedings, which are inherently unpredictable and could materially adversely affect our business, results of operations, financial condition, and cash flows.new
7. Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our business, results of operations, financial condition, and cash flows.
8. The outcome of Medtronic, Inc.'s U.S. tax litigation could have a material adverse impact on our financial condition.
9. We rely on the proper function, security and availability of our information technology systems and data, as well as those of third parties throughout our global supply chain and our customer and payor base, to operate our business, and a breach, cyber-attack or other disruption to these systems or data could materially and adversely affect our business, results of operations, financial condition, cash flows, reputation or competitive position.Cybersecurity
10. The failure to comply with anti-corruption laws could materially adversely affect our business and result in civil and/or criminal sanctions.
11. Laws and regulations governing international business operations could adversely impact our business.
12. Our insurance program may not be adequate to cover future losses.
13. Climate change or legal, regulatory or market measures to address climate change may materially adversely affect our financial condition and business operations.
14. We are subject to environmental laws and regulations and the risk of environmental liabilities, violations and litigation.
15. We are subject to risks related to our sustainability practices and initiatives.

Read these in Item 1A · See the changes

1. Changes in the prices of our goods and services, customer purchasing patterns and stocking dynamics, and/or inflationary costs may have a material adverse effect on our business, results of operations, financial condition, and cash flows.
2. We are subject to a variety of risks associated with global operations that could adversely affect our profitability and operating results.
3. Consolidation in the healthcare industry and the growing prevalence of ASCs could have an adverse effect on our revenues and results of operations.reworded
4. Healthcare industry cost-containment measures could result in reduced sales of our medical devices and medical device components.
5. The continuing development of many of our products depends upon us maintaining strong relationships with healthcare professionals.
6. Market disruptions resulting in diminished liquidity, or strikes or other work stoppages by healthcare professionals or staff, could adversely affect our revenues, results of operation, or financial condition.reworded

Read these in Item 1A · See the changes

1. The ongoing separation of our Diabetes Business could be delayed, may not be completed as currently contemplated, and could materially adversely affect our business, results of operations, financial condition, and cash flows.new

Read these in Item 1A · See the changes

1. We are incorporated in Ireland, and our jurisdiction of incorporation may subject us to risks that could adversely affect our business and holders of our securities.new
2. A transfer of our shares, other than ones effected by means of the transfer of book-entry interests in the Depository Trust Company, may be subject to Irish stamp duty.
3. As an Irish public limited company, we are required to obtain shareholder approval for certain capital structure decisions, which may limit our flexibility to manage our capital structure.reworded
4. In certain limited circumstances, dividends we pay may be subject to Irish dividend withholding tax and dividends received by Irish residents and certain other shareholders may be subject to Irish income tax.
5. Our shares received by means of a gift or inheritance could be subject to Irish capital acquisitions tax.

Read these in Item 1A · See the changes

Headings in the FY2025 10-K with no match this year.

1. Our success depends on our ability to differentiate our product and keep pace with emerging technologies.
2. Future potential changes to the U.S. tax laws could result in us being treated as a U.S. corporation for U.S. federal tax purposes, and the IRS may not agree with the conclusion that we should be treated as a foreign corporation for U.S. federal income tax purposes.
3. Legislative or other governmental action relating to the denial of U.S. federal or state governmental contracts to U.S. companies that redomicile abroad could adversely affect our business.
4. We are incorporated in Ireland, and Irish law differs from the laws in effect in the U.S. and may afford less protection to holders of our securities.